BPC-157 vs TB-500: how the two research peptides compare

BPC-157 and TB-500 sit among the most-studied compounds in tissue-repair and recovery research, and the two travel together constantly. They are different molecules running on different mechanisms, which is exactly why researchers keep setting them next to each other. This guide lays out what each one is, what the literature actually examines, and how each is supplied to US laboratories, so you can tell an evidence-backed comparison from the benefit lists that fill most search results.

Research use only. This compares two compounds as materials for in-vitro laboratory research. It is not guidance on human or animal use, nothing here is dosing or medical advice, and neither compound has been evaluated by the FDA.

The molecules themselves

• BPC-157 is a synthetic pentadecapeptide, fifteen amino acids, matching a sequence first identified in gastric juice. See what is BPC-157?
• TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring protein tied to cell structure and motility. See what is TB-500?

That distinction matters before any experiment starts: one is a short peptide that stands alone, the other a fragment modeled on a much larger regulatory protein, and they behave accordingly in study models. It also shapes how each is verified on a certificate, since a short defined sequence and a protein-derived fragment are not confirmed in quite the same way.

What the literature actually studies

It helps to separate what the primary literature examines from what is claimed downstream, because both compounds attract far more marketing than the published work supports. The research on each is largely in-vitro and preclinical: cultured cells and animal models, with results that shift by concentration, exposure time and model system.

• BPC-157 shows up mostly around angiogenesis and growth-factor signaling, with work exploring models of tendon, ligament and gastrointestinal-tissue repair. A 2025 systematic review is a useful map of what has and has not been studied.
• TB-500 research leans on actin regulation and cell migration. Tβ4 binds actin, so the fragment is studied for how it shapes cell movement and distribution in repair models.

Put simply, the BPC-157 literature clusters around vascular and growth-factor pathways, and the TB-500 literature around the cytoskeleton and cell mobility. What almost no primary study covers is the two compounds used together in one system; claims about the pairing are extrapolations from the single-compound work, not findings about the combination.

Local versus systemic

One shorthand researchers use to tell them apart: BPC-157 turns up more in localized settings, gut-tissue models included, while TB-500 is discussed more in terms of systemic distribution and cell migration across tissues. Those complementary angles are part of why the two keep appearing in the same study designs. Treat the shorthand as a rough map rather than a rule, since the framing depends heavily on the model and the endpoint.

The case for studying them together

Their proposed mechanisms do not overlap so much as complement: one examined around vascular and growth-factor pathways, the other around cell migration, and that is the usual rationale for pairing them. A single characterized vial also removes a practical variable, because two separate preparations mean two reconstitutions and two chances for concentration drift. It is why we offer the two pre-combined as the Wolverine Stack; see what is the Wolverine Stack?. The limitation is the mirror image of the benefit: a combined preparation cannot tell you which compound produced an observed effect, so protocols that need attribution run the singles as well.

Supply and format: pre-mixed, not powder

Most US listings of BPC-157 and TB-500 are lyophilized powder that the laboratory reconstitutes before use, and reconstitution introduces variability at every step: solvent choice, pH and how completely the material dissolves. Both compounds, as we supply them, ship instead as a pre-mixed solution prepared under controlled conditions, which removes that step entirely. The trade-off is handling: a solution has to stay refrigerated and travel cold-chain. The pre-mixed vs lyophilized guide sets out the comparison in full, and the peptide calculator handles concentration arithmetic if you are working from a powder.

Handling and verification

Both are peptides, so the practical demands are similar: keep the cold chain, limit freeze-thaw cycles, and start from a batch-specific Certificate of Analysis that confirms HPLC purity and mass-spectrometry identity. For our US vials there is no reconstitution step, since they arrive as solutions; for powder from other suppliers, reconstitute carefully and record the solvent and volume you used. See how to store research peptides.

How BPC-157 and TB-500 ship in the United States

For US laboratories, BPC-157 and TB-500 are each supplied as a pre-mixed vial with a batch-specific Certificate of Analysis that reports HPLC for purity and mass spectrometry for identity. Every compound is synthesized in our own UK laboratory rather than imported and repackaged, and each US batch is verified in a US laboratory before it ships. Orders are dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day, priced in US dollars and payable by Visa, Mastercard or Apple Pay. Store the vials refrigerated at 2-8°C on arrival, not frozen. The two are also available pre-combined as the Wolverine Stack.

Picking one for your work

Neither wins in the abstract; the right pick follows from your model and the endpoint you are after. If the question sits with vascular or growth-factor pathways, the BPC-157 literature is the deeper starting point; if it is cell migration and the cytoskeleton, TB-500 is the closer match. Plenty of designs simply include both, which is the case for pairing rather than choosing.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for either compound. Both are supplied strictly for in-vitro laboratory research and are not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually supplied. Experimental concentrations are specific to the model and endpoint and belong in the primary literature.

Browse BPC-157, TB-500, and the Wolverine Stack, or see the full healing & recovery collection.